ABL Balance Sheet - Abbott Laboratories

Watchlist Manager

Watchlist

Price: 97.2 EUR -1.61% Market Closed

Market Cap: €169.1B

Financial profile · Q3 FY2026

A cash-generative healthcare portfolio carrying a larger acquisition-funded debt burden

Abbott has generated positive free cash flow throughout the supplied annual history, with capital spending absorbing a minority of operating cash generation. Revenue growth has been uneven, and reported earnings have fluctuated more than cash generation.

What is developing

The debt-funded Exact Sciences acquisition has enlarged the revenue base and balance-sheet commitments without a corresponding increase in trailing operating profit. The latest quarter's operating-margin recovery did not prevent lower earnings and free cash flow, making the cash available for debt reduction an important distinction from sales growth.

What matters next

Whether free cash flow after dividends supports continued debt reduction without further depletion of cash balances.

Metric	FY2016 Dec 2016	FY2017 Dec 2017	FY2018 Dec 2018	FY2019 Dec 2019	FY2020 Dec 2020	FY2021 Dec 2021	FY2022 Dec 2022	FY2023 Dec 2023	FY2024 Dec 2024	FY2025 Dec 2025
Cash & Cash Equivalents	18.6B	9.4B	3.8B	3.9B	6.8B	9.8B	9.9B	6.9B	7.6B	8.5B
Cash Equivalents	18.6B	9.4B	3.8B	3.9B	6.8B	9.8B	9.9B	6.9B	7.6B	8.5B
Short-Term Investments	155m	203m	242m	280m	310m	450m	288m	383m	351m	417m
Total Receivables	3.2B	5.2B	5.2B	5.4B	6.4B	6.5B	6.2B	6.6B	6.9B	7.9B
Accounts Receivables	3.2B	5.2B	5.2B	5.4B	6.4B	6.5B	6.2B	6.6B	6.9B	7.9B
Other Receivables	0	0	0	0	0	0	0	0	0	0
Inventory	2.4B	3.6B	3.8B	4.3B	5B	5.2B	6.2B	6.6B	6.2B	6.5B
Other Current Assets	2.3B	1.7B	1.6B	1.8B	1.9B	2.3B	2.7B	2.3B	2.6B	2.6B
Total Current Assets	26.8B	20.1B	14.6B	15.7B	20.4B	24.2B	25.2B	22.7B	23.7B	26B
PP&E Net	5.7B	7.6B	7.6B	9B	10.1B	10.1B	10.3B	11.3B	11.7B	12.9B
PP&E Gross	5.7B	7.6B	7.6B	9B	10.1B	10.1B	10.3B	11.3B	11.7B	12.9B
Accumulated Depreciation	(6.7B)	(7.7B)	(8.1B)	(8.8B)	(9.8B)	(10.4B)	(11.1B)	(11.8B)	(12.1B)	(13.4B)
Intangible Assets	4.5B	21.5B	18.9B	17B	14.8B	12.7B	10.5B	8.8B	6.6B	5.5B
Goodwill	7.7B	24B	23.3B	23.2B	23.7B	23.2B	22.8B	23.7B	23.1B	24B
Long-Term Investments	2.9B	883m	897m	883m	821m	816m	766m	799m	886m	918m
Other Long-Term Assets	5B	2.1B	1.9B	2.1B	2.6B	4.1B	4.9B	6B	15.4B	17.3B
Other Assets	7.7B	24B	23.3B	23.2B	23.7B	23.2B	22.8B	23.7B	23.1B	24B
Total Assets	52.7B	76.3B	67.2B	67.9B	72.5B	75.2B	74.4B	73.2B	81.4B	86.7B
Accounts Payable	1.2B	2.4B	3B	3.3B	3.9B	4.4B	4.6B	4.3B	4.2B	4.2B
Accrued Liabilities	3.3B	4.8B	4.9B	5.2B	6.6B	6.8B	7.4B	7B	6.8B	7.6B
Short-Term Debt	868m	206m	200m	201m	213m	0	0	0	0	0
Current Portion of Long-Term Debt	3m	508m	7m	1.3B	7m	754m	2.3B	1.1B	1.5B	3B
Other Current Liabilities	1.4B	1B	963m	950m	1.2B	1.1B	1.2B	1.4B	1.6B	1.7B
Total Current Liabilities	6.7B	8.9B	9B	10.9B	11.9B	13.1B	15.5B	13.8B	14.2B	16.5B
Long-Term Debt	20.7B	27.2B	19.4B	16.1B	18.5B	17.3B	14.5B	13.6B	12.6B	9.9B
Deferred Income Tax	356m	2B	2.1B	1.5B	1.4B	1.4B	991m	568m	512m	559m
Minority Interest	179m	201m	198m	213m	219m	222m	219m	224m	237m	641m
Other Liabilities	4.3B	7B	6B	8.1B	7.7B	7.4B	6.5B	6.4B	6.2B	7B
Total Liabilities	32.1B	45.4B	36.6B	36.8B	39.8B	39.4B	37.8B	34.6B	33.8B	34.6B
Common Stock	13B	23.2B	23.5B	23.9B	24.1B	24.5B	24.7B	24.9B	25.2B	25.5B
Retained Earnings	25.6B	24B	24.6B	25.8B	27.6B	31.5B	35.3B	37.6B	47.3B	49.8B
Unrealized Security Profit/Loss	(69m)	(5m)	0	0	—	—	—	—	—	—
Treasury Stock	(10.8B)	(10.2B)	(10B)	(10.1B)	(10B)	(11.8B)	(15.2B)	(16B)	(16.8B)	(17.2B)
Other Equity	(7.2B)	(6.1B)	(7.6B)	(8.5B)	(8.9B)	(8.4B)	(8.1B)	(7.8B)	(7.9B)	(6B)
Total Equity	20.5B	30.9B	30.5B	31.1B	32.8B	35.8B	36.7B	38.6B	47.7B	52.1B
Total Liabilities & Equity	52.7B	76.3B	67.2B	67.9B	72.5B	75.2B	74.4B	73.2B	81.4B	86.7B
Common Shares Outstanding	1.5B	1.7B	1.8B	1.8B	1.8B	1.8B	1.7B	1.7B	1.7B	1.7B